This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sueta, C. A. Articles by Adams, K. F. Search for Related Content PubMed PubMed Citation Articles by Sueta, C. A. Articles by Adams, K. F., Jr

Circulation, Vol 89, 660-666, Copyright © 1994 by American Heart Association

ARTICLES

Effect of acute magnesium administration on the frequency of ventricular arrhythmia in patients with heart failure

CA Sueta, SW Clarke, SH Dunlap, L Jensen, MB Blauwet, G Koch, JH Patterson and KF Adams Jr
Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill 27599-7075.

BACKGROUND: There is a high incidence of ventricular arrhythmia and sudden death in patients with heart failure. Unfortunately, currently available antiarrhythmic agents have only limited efficacy and may result in proarrhythmia and hemodynamic deterioration in these patients. METHODS AND RESULTS: We studied the acute effect of intravenous magnesium chloride on the frequency and severity of ventricular arrhythmia in 30 patients with symptomatic heart failure using a double-blind, placebo-controlled crossover design. The left ventricular ejection fraction was 23.0 +/- 8.0% (mean +/- SD). No patient had a history of symptomatic ventricular arrhythmia or was receiving antiarrhythmic agents, calcium channel antagonists, or beta- blockers. Patients were randomized to receive placebo (5% dextrose [D5W] in water alone) or magnesium chloride in D5W given as a bolus of 0.3 mEq/kg over 10 minutes followed by a maintenance infusion of 0.08 mEq/kg per hour for 24 hours. The magnesium concentrations 30 minutes and 24 hours after the bolus were 3.6 +/- 0.1 and 4.2 +/- 0.1 mg/dL, respectively. There was no significant change in serum potassium concentration during magnesium administration. Blinded analysis revealed that administration of intravenous magnesium chloride, compared with placebo, significantly decreased total ventricular ectopy per hour (mean +/- SEM, 70 +/- 26 versus 149 +/- 64, P < .001), couplets per day (23 +/- 11 versus 94 +/- 59, P = .007), and episodes of ventricular tachycardia per day (0.8 +/- 0.2 versus 2.6 +/- 1.0, P = .051). CONCLUSIONS: Intravenous magnesium chloride administration reduces the frequency of ventricular arrhythmia in patients with symptomatic heart failure.

This article has been cited by other articles:

				S. E. Lehnart, X. H.T. Wehrens, P. J. Laitinen, S. R. Reiken, S.-X. Deng, Z. Cheng, D. W. Landry, K. Kontula, H. Swan, and A. R. Marks Sudden Death in Familial Polymorphic Ventricular Tachycardia Associated With Calcium Release Channel (Ryanodine Receptor) Leak Circulation, June 29, 2004; 109(25): 3208 - 3214. [Abstract] [Full Text] [PDF]

				P Kaye and I O'Sullivan The role of magnesium in the emergency department Emerg. Med. J., July 1, 2002; 19(4): 288 - 291. [Abstract] [Full Text] [PDF]

				Y. Murasato, Y. Harada, M. Ikeda, Y. Nakashima, and Y. Hayashida Effect of Magnesium Deficiency on Autonomic Circulatory Regulation in Conscious Rats Hypertension, August 1, 1999; 34(2): 247 - 252. [Abstract] [Full Text] [PDF]

				G. Tudor and G. G Koch Review of nonparametric methods for the analysis of crossover studies Statistical Methods in Medical Research, December 1, 1994; 3(4): 345 - 381. [Abstract] [PDF]